Volume 5.44 | Nov 7

Cord Blood News 5.44 November 7, 2013
Cord Blood News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Cord Blood News on Twitter
 
TOP STORY
CD133 Is a Positive Marker for a Distinct Class of Primitive Human Cord Blood-Derived CD34-Negative Hematopoietic Stem Cells
Using 18 lineage-negative (Lin)CD34-negative (CD34) cells, researchers analyzed the expression of candidate positive markers by FCM. They finally identified CD133 as a reliable positive marker of human CB-derived CD34 SCID-repopulating cells and succeeded in highly purifying primitive human CD34 hematopoietic stem cells. [Leukemia] Abstract
Technical Bulletin: Assays For Cord Blood
 
PUBLICATIONS (Ranked by impact factor of the journal)
Biomimetic Macroporous PEG Hydrogels as 3D Scaffolds for the Multiplication of Human Hematopoietic Stem and Progenitor Cells
A straight-forward, easy-to-use method for the production of biofunctionalized, macroporous hydrogel scaffolds that mimic the spongy architecture of trabecular bones was developed. As surrogates for cellular components of the niche, mesenchymal stem cells from different sources (bone marrow and umbilical cord) and osteoblast-like cells were tested. [Biomaterials] Abstract

Human Amniotic Fluid-Derived Mesenchymal Cells from Fetuses with a Neural Tube Defect Do Not Deposit Collagen Type I Protein after TGF-ß1 Stimulation In Vitro
Scientists found that cells derived from fetuses with a neural tube defect, in contrast to healthy human amniotic fluid cells, did not deposit collagen type I. Furthermore, the neural tube defect cells showed, compared to both healthy amniotic fluid cells and fetal fibroblasts, much lower mRNA expression levels of genes that are involved in collagen biosynthesis. [Stem Cells Dev] Abstract

Umbilical Cord Blood as an Alternative Source of Reduced-Intensity Hematopoietic Stem Cell Transplantation for Chronic Epstein-Barr Virus-Associated T- or NK-Cell Lymphoproliferative Diseases
Recently scientists reported that reduced-intensity conditioning (RIC) provided better outcomes than myeloablative conditioning because RIC was less toxic. However, it was unclear whether cord blood transplantation (CBT) works in the context of RIC. In this study they retrospectively analyzed 17 patients who underwent RIC followed by bone marrow transplantation and 15 patients who underwent RIC followed by CBT. [Biol Blood Marrow Transplant] Abstract

Prevention of GVHD by Adoptive T Regulatory Therapy Is Associated with Active Repression of Peripheral Blood Toll-Like Receptor-5 mRNA Expression
In a Phase I study, adoptive transfer of expanded CD4+CD25+Foxp3+ natural regulatory T cells (nTregs) resulted in a reduced incidence of grade II-IV graft-versus-host disease (GVHD). To investigate potential mechanisms responsible for the reduced GVHD risk, scientists analyzed peripheral blood mononuclear cell mRNA expression of a tolerance gene set previously identified in operational tolerant kidney transplant recipients, comparing healthy controls to patients who received no nTregs or nTregs with and without GVHD. [Biol Blood Marrow Transplant] Abstract

Genomic Alterations in Human Umbilical Cord-Derived Mesenchymal Stromal Cells Call for Stringent Quality Control before Any Possible Therapeutic Approach
It is still unclear whether umbilical cord-mesenchymal stromal cells (UC-MSCs) are prone or not to the acquisition of genomic imbalances during in vitro expansion. With the use of array-comparative genomic hybridization, scientists compared copy number variations of early and late passages of in vitro-expanded UC-MSCs. [Cytotherapy] Abstract

Fetal Mesenchymal Stromal Cells from Cryopreserved Human Chorionic Villi: Cytogenetic and Molecular Analysis of Genome Stability in Long-Term Cultures
Human mesenchymal stromal cells (hMSC) from chorionic villi (CV) were monitored for genetic stability in long-term cultures. Researchers set up a good manufacturing practice cryopreservation procedure for small amounts of native CV samples. After isolation, hMSC were in vitro cultured and analyzed for biological end points. [Cytotherapy] Abstract

Reduction of Fibrosis in Dibutyltin Dichloride-Induced Chronic Pancreatitis Using Rat Umbilical Mesenchymal Stem Cells From Wharton’s Jelly
Researchers investigated the effects of rat umbilical cord mesenchymal stem cells from Wharton’s jelly on dibutyltin dichloride-induced chronic pancreatitis and subsequent pancreatic fibrosis in rats. [Pancreas] Abstract

Intra-Arterial Transplantation of Human Umbilical Cord Blood Mononuclear Cells in Neonatal Hypoxic-Ischemic Rats
Researchers investigated the feasibility of intra-arterial transplantation of human umbilical cord blood mononuclear cells for the treatment of long-term behavior dysfunction and brain lesion after neonatal hypoxia-ischemia. [Life Sci] Abstract

Electrophysiological Characterization of Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells Induced by Olfactory Ensheathing Cell-Conditioned Medium
Until now, little work has been focused on the differentiation of umbilical cord blood-derived marrow stromal cells (UCB-MSCs). In this work, UCB-MSCs were demonstrated to be negative for CD34 and CD45 expression but positive for CD90 and CD105 expression. [Neurochem Res] Abstract

Use TeSR-E7 to generate iPS cells with high quality colony morphology for easy identification and rapid subcloning. Request your sample.
 
REVIEWS
Current and Future Approaches to Treat Graft Failure after Allogeneic Hematopoietic Stem Cell Transplantation
The authors summarize current approaches to treat graft failure/rejection after hematopoietic stem cell transplantation, and they discuss new strategies of graft manipulation and immune therapy of particular interest for preventing/treating this complication. [Expert Opin Pharmacother] Abstract

Visit our reviews page to see a complete list of reviews in the cord blood research field.

Enter to Win: Free ISCT 2014 Conference Registration in Paris, France!
 
INDUSTRY NEWS
Polaris Group Announces Treatment of First Patient in Phase II Study of ADI-PEG 20 in Acute Myeloid Leukemia
Polaris Group announced that the first patient has been dosed in its Phase II trial of ADI-PEG 20, arginine deiminase formulated with polyethylene glycol, for the treatment of Relapsed/Refractory Acute Myeloid Leukemia. [PR Newswire Association LLC] Press Release

The Leukemia & Lymphoma Society Applauds FDA’s Approval of Gazyva® as First-Line Treatment for Patients with Chronic Lymphocytic Leukemia
The U.S. Food and Drug Administration’s (FDA’s) approval of Gazyva® is an important advance for patients diagnosed with chronic lymphocytic leukemia (CLL). Gazyva, the first treatment approved through the FDA’s breakthrough therapy designation, is indicated in combination with chlorambucil to treat previously untreated patients with CLL. [The Leukemia & Lymphoma Society] Press Release

Delete Blood Cancer Announces the Start of Bone Marrow Awareness Month
Blood cancer is the second leading cause of all cancer deaths in the United States. To lend greater awareness to a solution to this issue, Delete Blood Cancer DKMS announced that November is Bone Marrow Awareness Month. [PR Newswire Association LLC] Press Release

From our sponsor: Free human hematopoietic progenitors wallchart. Request your copy.
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW Danish Stem Cell Society’s 3rd Symposium
March 7-8, 2014
Nyborg, Denmark

Visit our events page to see a complete list of events in the cord blood community.
 
JOB OPPORTUNITIES
NEW Clinical Researcher – Hematopoietic Stem Cell Transplant Program (Northwestern University- Feinberg School of Medicine)

Postdoctoral Research Fellows – Isolation of Stem Cells from Placenta and Amniotic Fluid (Wake Forest Institute for Regenerative Medicine)

Adult Stem Cell Transplant Physician (John Theurer Cancer Center)

PhD Studentship – Identifying Drugs to Improve the Utility of Bone Marrow and Cord Blood Transplantation (Cardiff University)

Postdoctoral Position – Human Pluripotent and Hematopoietic Stem Cell Bioinformatics (Albert Einstein College Medicine)

Translational Clinician-Scientist – Stem Cell Transplantation (Boston Children’s Hospital)

Postdoctoral Position – Patient-Specific Stem Cell Lines: Disease Modeling, Repair and Transplantation (Columbia University)

Postdoctoral Position – Cellular and Genetic Therapies for Hemoglobinopathies (Blood Systems Research Institute)

Faculty Positions – Stem Cells and Regenerative Medicine (Baylor College of Medicine)

Scientist – Particle Chemistry (STEMCELL Technologies Inc.)

Research Technologist – Human Pluripotent Stem Cell Products (STEMCELL Technologies Inc.)

Research Associate/Scientist – Antibodies Group (STEMCELL Technologies Inc.)

Research Associate – Particle Chemistry (STEMCELL Technologies Inc.)



Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.
Learn more about Cord Blood News: Archives | Events | Contact Us